Current stage -Stage II - Page 2 of 14 Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Evaluating the effectiveness of tadalafil for the treatment of lower urinary tract symptoms and erectile dysfunction after low-dose-rate brachytherapy for prostate cancer

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness of phosphodiesterase-5 (PDE5) inhibitor tadalafil (Cialis) for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) after low-dose-rate (LDR) brachytherapy (BT) in patients with localized prostate cancer. The data showed that tadalafil improved the LUTS and ED outcomes...

Read More

Urinary, sexual outcomes and tumor control after robot-assisted laparoscopic radical prostatectomy in localized prostate cancer

Urinary, sexual outcomes and tumor control after robot-assisted laparoscopic radical prostatectomy in localized prostate cancer

Posted by on Mar 14, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the urinary, sexual, and tumor control outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) over time in patients with localized prostate cancer. The study found that analyzing these three outcomes is beneficial for these patients. Some background Localized prostate cancer (PCa) is a form of...

Read More

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Searching for patients with confined prostate cancer to trial a cryoablation procedure

Posted by on Mar 13, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is looking to examine the use of a new treatment software (UroNAV Ablation) system in treating confined prostate cancer with cryoablation. The main outcomes to be measured will be device/treatment-related complications and tumor control. This trial is being carried out in New York, US.  The details Localized...

Read More

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Posted by on Mar 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and functional outcomes of using the Retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) as a salvage treatment for patients with localized prostate cancer (PCa). The study found that the sRS-RARP approach was associated with good urinary and oncological outcomes in these...

Read More

Evaluating long-term outcomes after high-intensity focused ultrasound for prostate cancer

Evaluating long-term outcomes after high-intensity focused ultrasound for prostate cancer

Posted by on Feb 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients who underwent whole-gland high-intensity focused ultrasound (HIFU) for non-metastatic prostate cancer. The data showed that HIFU has favorable outcomes in low- and intermediate-risk groups of patients. Some background HIFU is a treatment option for prostate...

Read More

Evaluating long-term active surveillance for early-stage prostate cancer.

Evaluating long-term active surveillance for early-stage prostate cancer.

Posted by on Dec 28, 2020 in Prostate cancer | 0 comments

In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...

Read More

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Should patients with prostate cancer get androgen deprivation therapy before or after radiotherapy?

Posted by on Dec 20, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of giving androgen deprivation therapy (ADT) before or after radiotherapy (RT) for prostate cancer (PCa). The study found that treatment with RT followed by ADT increased patient survival without the spread of the disease. Some background PCa can often spread to other locations within the...

Read More

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Comparing whole-pelvis vs prostate only radiotherapy in patients with high-risk prostate cancer

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the use of radiotherapy for prostate cancer in two areas: the prostate only, or the whole pelvis. The results showed that, for high-risk patients, radiotherapy of the whole pelvis improved patient outcomes. Some background For patients with medium or high-risk prostate cancer, the standard treatment is...

Read More

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Are radiotherapy and surgery equally good at treating localized prostate cancer?

Posted by on Sep 26, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared surgery and radiotherapy for treating localized prostate cancer. They found no significant difference in survival between the two treatments. Some background Localized prostate cancer (cancer which has not spread beyond the prostate gland) can be treated with either surgery, radiotherapy, or monitoring without...

Read More

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of apalutamide (A; Erleada), darolutamide (D; Nubeqa), and enzalutamide (E; Xtandi) in treating nonmetastatic castration-resistant prostate cancer (nmCRPC). The authors found that A and E had better metastasis-free survival (MFS) compared to D. Some background Men with CRPC fail to respond to...

Read More

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Evaluating the risk of secondary cancers after internal radiation therapy in patients with prostate cancer

Posted by on Jun 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study looked at the long-term risk of secondary cancers following brachytherapy (BT; internal radiation therapy) for prostate cancer. It found that treating prostate cancer with BT had a low risk of secondary cancers. Some background Prostate cancer is a slow-growing cancer of the prostate gland. Men with prostate cancer that has...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2023 Medivizor